Latest / The Well-Built Life / HIV Prevention: Access and Innovation in Latin America
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to the Well Built Life. I
- 0:03Speaker 1: am really glad you are here today. This is a
- 0:05Speaker 1: space where we cut through the complicated trends and confusing
- 0:09Speaker 1: advice to talk about what actually works for your health, fitness,
- 0:12Speaker 1: and overall well being. No intense jargon, no extreme rules,
- 0:17Speaker 1: just simple practical tips you can easily fit into your
- 0:20Speaker 1: everyday routine to feel a little stronger, healthier, and more balanced.
- 0:25Speaker 1: Grab a drink, get comfortable, and let us dive into
- 0:28Speaker 1: today's conversation. Hey everyone, welcome back to the Well Built Life.
- 0:35Speaker 1: I am really glad you are here today. This is
- 0:37Speaker 1: a space where we cut through the complicated trends and
- 0:40Speaker 1: confusing advice to talk about what actually works for your health, fitness,
- 0:44Speaker 1: and overall well being. No intense jargon, no extreme rules,
- 0:49Speaker 1: just simple practical tips you can easily fit into your
- 0:52Speaker 1: everyday routine to feel a little stronger, healthier, and more balanced.
- 0:57Speaker 1: Grab a drink, get comfortable, and let us dive in
- 1:00Speaker 1: to today's conversation. Today we re talking about lenikupavir, another
- 1:05Speaker 1: groundbreaking drug in the fight against HIV. Developed by Gilead Sciences.
- 1:10Speaker 1: This treatment boasts near one hundred percent efficacy with just
- 1:14Speaker 1: twice yearly shots. Imagine that once or twice a year
- 1:19Speaker 1: to keep you healthy and strong. But here s where
- 1:22Speaker 1: things get a bit well, let's say they renot quite
- 1:25Speaker 1: as simple. First off, the price tag is staggering. In
- 1:30Speaker 1: the United States, lennikupever costs fourteen thousand dollars per dose. Yes,
- 1:35Speaker 1: that is right, thirteen grand for one shot. Meanwhile, in
- 1:39Speaker 1: one hundred and twenty low and middle income countries, generic
- 1:43Speaker 1: versions are licensed at a mere forty dollars per dose.
- 1:47Speaker 1: Can you believe it? It S like the difference between
- 1:50Speaker 1: buying a fancy car and getting a used bike. Now,
- 1:54Speaker 1: let me tell you about Latin america S struggle with
- 1:57Speaker 1: this dilemma. Countries like Brazil, Mexi, Pico, Argentina, and Peru
- 2:02Speaker 1: find themselves in an awkward middle ground. They don't te
- 2:05Speaker 1: qualify for the reduced prices offered to some lower income nations,
- 2:09Speaker 1: but can tea afford the sky high US price either.
- 2:14Speaker 1: It as a bit of a paradox, isn't tie it?
- 2:17Speaker 1: They are trying their best to keep up with innovation
- 2:20Speaker 1: while being held back by financial constraints. Activists have taken
- 2:24Speaker 1: to streets and conferences demanding affordable access. During the International
- 2:29Speaker 1: aid Society Conference in Rio de Janio, they chanted Farma
- 2:34Speaker 1: greed is killing us. Their message rings loud and clear.
- 2:37Speaker 1: We want our health without breaking the bank. And you
- 2:40Speaker 1: know who s at the forefront of this fight. The
- 2:43Speaker 1: Brazilian Health Minister, doctor Alexandre Padilha He criticized gilead S
- 2:49Speaker 1: pricing strategy as an injustice to deny access due to
- 2:52Speaker 1: innovation without affordability. UNAIDS Executive Director Winnie bian Yima echoed
- 2:57Speaker 1: these sentiments, urging Brazil not to be forced into a
- 3:00Speaker 1: lower priority in negotiations with Gilead. It as a tough
- 3:05Speaker 1: spot for everyone involved, innovators trying hard but facing the
- 3:10Speaker 1: harsh reality of cost barriers. A spokesperson from Gilead stated
- 3:14Speaker 1: they are negotiating directly with regional Latin American governments, but
- 3:18Speaker 1: no one seems particularly thrilled about the timeline or price.
- 3:22Speaker 1: Despite all this drama, there is some good news too.
- 3:25Speaker 1: Long acting prep drugs like lennakapevir offer significant opportunities in
- 3:29Speaker 1: HIV control and administration ease compared to daily pills, but
- 3:33Speaker 1: for now these drugs are only licensed for twice yearly
- 3:37Speaker 1: used starting twenty twenty five, with manufacturing capacities still building up.
- 3:42Speaker 1: It as a bit of a weight and see game.
- 3:45Speaker 1: In the meantime, Brazil is taking matters into its own
- 3:48Speaker 1: hands by collaborating with Fiocruz and MESTY Brazil to explore
- 3:53Speaker 1: alternative pricing strategies and vive healthcare s. CABOTEH Gervier will
- 3:58Speaker 1: be incorporated into brazil S PREP program through SUS the
- 4:02Speaker 1: public health system by the end of this year due
- 4:05Speaker 1: to acceptable pricing. It a step in the right direction,
- 4:09Speaker 1: but there still much work to do. So what can
- 4:13Speaker 1: you do today? Well, for starters, stay informed about these
- 4:16Speaker 1: issues and support organizations working towards affordable access. Small steps
- 4:21Speaker 1: might not seem like much on their own, but together
- 4:23Speaker 1: they make a difference. Remember every dollar counts when it
- 4:27Speaker 1: comes to health and well being. All right, let test
- 4:31Speaker 1: dive into today s topic, activist protests and government responses
- 4:36Speaker 1: in Brazil regarding affordable access to new HIV prevention methods.
- 4:40Speaker 1: It as a tale that perfectly blends innovation with corporate greed,
- 4:45Speaker 1: sounding almost like a dark comedy script. First off, activists
- 4:50Speaker 1: at the International Aid Society Conference in Rio de Janeiro
- 4:54Speaker 1: couldn't t hold back their frustration, they chanted pharma greed
- 4:59Speaker 1: is killing us and rightfully demanded more affordable access to
- 5:02Speaker 1: new drugs like lennecapevir. This drug from Gilead Sciences has
- 5:07Speaker 1: near one hundred percent efficacy with just two shots a year,
- 5:10Speaker 1: but the price tag of fourteen thousand dollars per dose
- 5:13Speaker 1: in the US makes it out of reach for most.
- 5:15Speaker 1: Now here s where things get tricky. Brazil and its
- 5:19Speaker 1: neighbors Mexico, Argentina and Peru are stuck as upper middle
- 5:24Speaker 1: income countries that don't Tea qualify for reduced prices from Gilead,
- 5:29Speaker 1: yet still can Tea afford to pay full price. It
- 5:33Speaker 1: is a classic case of being in the wrong income bracket.
- 5:36Speaker 1: With activists protests echoing through conference halls, brazil Self Minister
- 5:41Speaker 1: doctor Alexandre Padilha stepped up to criticize Gilead directly. He argued,
- 5:46Speaker 1: innovatively without affordability is an injustice that denies access based
- 5:50Speaker 1: on innovation alone, a clever jab at corporate priorities. Meanwhile,
- 5:55Speaker 1: UNAIDS executive director Winnie Bianima chimed in, urging Brazil not
- 6:00Speaker 1: to be forced into lower priority negotiations with Gilead. On
- 6:04Speaker 1: the other hand. Gilead is in Tea exactly sitting still.
- 6:08Speaker 1: They are negotiating directly with regional Latin American governments, but
- 6:12Speaker 1: remain tight lipped about pricing and timelines. This strategic silence
- 6:17Speaker 1: does nt help build trust or transparency. In a bid
- 6:21Speaker 1: for alternative solutions, Via Cruz signed a memorandum with MSD
- 6:25Speaker 1: Brazil to explore manufacturing alamatravir. This could potentially offer an
- 6:30Speaker 1: affordable option despite the supply challenges, and guess what. Brazil
- 6:35Speaker 1: is also incorporating Vaive Healthcare as caba tagriver into its
- 6:39Speaker 1: prep program through SUS by the end of this year
- 6:41Speaker 1: because Gilead agreed on acceptable pricing terms. Cabatagriver, a long
- 6:46Speaker 1: acting prep drug, offers significant opportunities in HIV control and
- 6:51Speaker 1: administration ease compared to daily pills. But here is the kicker.
- 6:55Speaker 1: Even with these efforts, Latin America still faces supply challenges
- 6:59Speaker 1: as co lena Capevir was only licensed for twice yearly
- 7:03Speaker 1: use starting in twenty twenty five. Manufacturing capacity is slowly
- 7:08Speaker 1: building up, making this timeline both hopeful and daunting. So
- 7:12Speaker 1: what can you do today? Stay informed about these issues
- 7:15Speaker 1: and support organizations working towards affordable access. Every bit of
- 7:19Speaker 1: awareness counts, especially when it comes to health and well being. Remember,
- 7:24Speaker 1: small steps collectively make a difference in the fight against HIV.
- 7:28Speaker 1: All right, So let s dive into some interesting challenges
- 7:32Speaker 1: and solutions in the world of HIV prevention and treatment,
- 7:36Speaker 1: specifically focusing on Gilead Sciences rollout strategy, biocrus s manufacturing efforts,
- 7:43Speaker 1: and Vaive Healthcare s Cabotake River integration into public health programs.
- 7:49Speaker 1: First up, Gilead Sciences. This company has really pushed boundaries
- 7:53Speaker 1: with their drug lena capevir, which could revolutionize HIV treatment
- 7:57Speaker 1: by offering near one hundred percent EFFICAI through just twice
- 8:01Speaker 1: yearly shots. But here is the catch. While this might
- 8:05Speaker 1: sound great on paper or rather in a PowerPoint, it
- 8:08Speaker 1: comes at quite a hefty price tag fourteen thousand dollars
- 8:11Speaker 1: per dose in the United States. That s not exactly
- 8:15Speaker 1: pocket change, even worse for Latin American countries like Brazil, Mexico, Argentina,
- 8:20Speaker 1: and Peru, which are stuck as upper middle income too
- 8:24Speaker 1: rich to get the cheap generic version but too poor
- 8:27Speaker 1: to afford the US prices. But wait, there is hope
- 8:31Speaker 1: on the horizon thanks to Fiocruz, a public health research
- 8:35Speaker 1: institute in Brazil. They re partnering with MSD Brazil, a
- 8:39Speaker 1: subsidiary of merk to explore manufacturing alamandrevir, which could offer
- 8:45Speaker 1: an alternative that s more affordable and accessible. This is
- 8:49Speaker 1: a significant step, but at s not without its challenges.
- 8:52Speaker 1: Manufacturing capacity is still being built up, making the timeline
- 8:56Speaker 1: both exciting and nerve racking. Now let's talk about vv
- 9:01Speaker 1: Healthcare s cabatake revere integration into public health programs in
- 9:06Speaker 1: Brazil through their National Universal Health system SUS. Despite some
- 9:10Speaker 1: criticism over gilead S rollout strategy, VIEV has managed to
- 9:15Speaker 1: secure a place for cabotah River in the PREP program.
- 9:18Speaker 1: This long acting version of PREP is easier to administer
- 9:21Speaker 1: than daily pills and offers significant opportunities for HIV prevention.
- 9:26Speaker 1: Brazil plans to incorporate it by the end of this
- 9:29Speaker 1: year due to its acceptable pricing, which means more people
- 9:32Speaker 1: could benefit from this treatment. So what can you do today?
- 9:37Speaker 1: Stay informed about these issues and support organizations working towards
- 9:41Speaker 1: affordable access to innovative treatments like cabatograver. Every bit of
- 9:45Speaker 1: awareness counts, especially when it comes to health and well being. Remember,
- 9:50Speaker 1: small steps collectively make a difference in the fight against HIV.
- 9:54Speaker 1: All right, let's dive into today s topic, future prospects
- 9:59Speaker 1: in HIV p prevention, long acting prep drugs, regional supply
- 10:04Speaker 1: chain issues, and UNAIDS goals for global access. First up,
- 10:08Speaker 1: we have a drug called lena capevir. This bad boy
- 10:11Speaker 1: is like the superhero of antiretrovirals. It works with just
- 10:15Speaker 1: two shots a year to prevent HIV infection. But here
- 10:19Speaker 1: s where things get interesting. In the United States, it
- 10:22Speaker 1: costs fourteen thousand dollars per dose OUCH, but fear not,
- 10:26Speaker 1: generic versions are much more affordable at around forty dollars
- 10:29Speaker 1: for one hundred and twenty low and middle income countries.
- 10:34Speaker 1: Now this brings us to a bit of regional drama.
- 10:37Speaker 1: Countries like Brazil, Mexico, Argentina and Peru face some tough
- 10:41Speaker 1: choices because they re upper middle income and thus done
- 10:45Speaker 1: Tea qualify for the cheaper prices, but can Tea afford
- 10:49Speaker 1: the US price tag. Activists are up in arms about this.
- 10:53Speaker 1: Their protests during the International Aid Society Conference in Rio
- 10:56Speaker 1: were fierce. Farma greed is killing us. They redemanding that
- 11:01Speaker 1: these life saving drugs be more accessible. Brazil S Health Minister,
- 11:05Speaker 1: doctor Alexandre Padilla, is Tea happy either. He calls gilead
- 11:11Speaker 1: S pricing strategy and injustice, and argues that people should
- 11:15Speaker 1: in Tea be denied access just because of the cost.
- 11:18Speaker 1: UNAIDS Executive director Winnie bian Yima agrees, urging Brazil to
- 11:23Speaker 1: not get pushed into a lower priority in negotiations with Gilead.
- 11:27Speaker 1: Gilead is currently negotiating directly with regional Latin American governments,
- 11:32Speaker 1: but has in Tea disclosed any details about pricing or timelines.
- 11:36Speaker 1: This all leads us to wonder why they recovering only
- 11:38Speaker 1: twenty four countries when there are so many more that
- 11:41Speaker 1: need this drug. They prioritize regions with greater HIV burdens
- 11:46Speaker 1: and limited financing capacity, which is in Tea exactly equitable.
- 11:50Speaker 1: In the meantime, Brazil is making headway by incorporating Vaive
- 11:54Speaker 1: health Care s cabote Graver into its PREP program through
- 11:59Speaker 1: SUS brazil S Unified Health System. Due to acceptable pricing,
- 12:04Speaker 1: this long acting version of PREP drugs offers significant opportunities
- 12:08Speaker 1: in HIV control and administration, easier than daily pills for sure,
- 12:14Speaker 1: but let's not forget the challenges ahead. The region faces
- 12:17Speaker 1: supply issues because lenacape of ear was only licensed for
- 12:20Speaker 1: twice yearly use starting twenty twenty five, and manufacturing capacity
- 12:25Speaker 1: is still building up. It is a race against time
- 12:28Speaker 1: to ensure these drugs are widely available where they re needed.
- 12:31Speaker 1: Most UNAIDS has set ambitious goals scale up access to
- 12:34Speaker 1: twenty million people within three years. However, current global vaccine
- 12:38Speaker 1: distribution capabilities exceed this target, which means other strategies need
- 12:43Speaker 1: to be in place too. So here s what you
- 12:46Speaker 1: can do today. Stay informed about these issues and support
- 12:49Speaker 1: organizations working towards affordable access to innovative treatments like Cabotigriever,
- 12:54Speaker 1: every bit of awareness counts, especially when it comes to
- 12:58Speaker 1: health and well being from small steps collectively make a
- 13:01Speaker 1: difference in the fight against HIV. That brings us to
- 13:04Speaker 1: the end of today as episode, Thank you so much
- 13:08Speaker 1: for spending part of your day with me. If you
- 13:10Speaker 1: found this episode s tip's helpful and want to make
- 13:13Speaker 1: sure you don't tea miss the next conversation, please take
- 13:16Speaker 1: a quick second to hit that subscribe or follow button
- 13:19Speaker 1: on whatever platform you are listening on. It is a
- 13:21Speaker 1: completely free way to support the show and helps more
- 13:24Speaker 1: people find us. This podcast is independently produced, so if
- 13:28Speaker 1: you re ever in a position where you'd d like
- 13:30Speaker 1: to help keep it running, we do accept small donations.
- 13:34Speaker 1: You can find a link right in the episode description
- 13:37Speaker 1: below to buy us a coffee or contribute what you can.
- 13:40Speaker 1: Every bit genuinely helps take care of yourself, stay balanced,
- 13:45Speaker 1: and we will talk again soon